Press coverage about AveXis (NASDAQ:AVXS) has been trending somewhat positive recently, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. AveXis earned a daily sentiment score of 0.23 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.6788869256557 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:
- AveXis (AVXS) to Release Earnings on Tuesday (americanbankingnews.com)
- AveXis (AVXS) Given Outperform Rating at Sanford C. Bernstein (americanbankingnews.com)
- AveXis to Report Fourth Quarter and Full Year 2017 Financial and Operating Results (finance.yahoo.com)
- AveXis Sees Unusually High Options Volume (AVXS) (americanbankingnews.com)
Shares of AveXis (AVXS) traded up $2.83 during trading on Thursday, hitting $119.53. The stock had a trading volume of 349,210 shares, compared to its average volume of 609,695. The firm has a market capitalization of $4,270.00 and a P/E ratio of -21.42. AveXis has a 12 month low of $53.94 and a 12 month high of $128.00.
In other news, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $94.77, for a total transaction of $168,690.60. Following the completion of the sale, the vice president now directly owns 1,780 shares in the company, valued at $168,690.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, VP Andrew F. Knudten sold 2,000 shares of the firm’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $94.48, for a total value of $188,960.00. Following the sale, the vice president now owns 7,000 shares of the company’s stock, valued at $661,360. The disclosure for this sale can be found here. Insiders have sold 57,560 shares of company stock valued at $6,160,062 over the last 90 days. Insiders own 18.60% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “AveXis (AVXS) Receives Daily Media Impact Rating of 0.23” was first posted by BBNS and is owned by of BBNS. If you are accessing this news story on another website, it was illegally copied and republished in violation of US and international copyright legislation. The correct version of this news story can be viewed at https://baseballnewssource.com/markets/avexis-avxs-receives-daily-media-impact-rating-of-0-23/1906168.html.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.